Member Info for EyeGuy

25% up nice

huge tick up. 22p ask

NT to buy - this should fly

21p paid

kezzman- that isn't true because SFX-01 is also used in subarachnoid haemorrhage with readouts due late summer. Not a one trick pony at all pal.

yep big news for me. took a few k here.

On 19 March 2019, the Company received a clarificatory letter from EBIOSS in relation to the terms of the Agreement and the Parties' intentions regarding the potential use of EQTEC's technology. EBIOSS has confirmed that, in respect of waste treatment and disposal projects, the Parties will use EQTEC's gasification technology, subject to successful completion of Urbaser technical due diligence and all parties, including EQTEC, agreeing terms, including the commercial basis of any contract. EQTEC confirms that it will conduct due diligence on any potential opportunities that are presented to it by the Parties pursuant to the Agreement.

Ian Price, CEO of EQTEC plc, commented: "We are pleased to note the Agreement between EBIOSS and Urbaser, and we are encouraged by this statement of intent by the Parties to use our technology and the further validation that this would bring to the Group.

too some. the agreement has been clarified. that is the point. great news

Im in at 1.10 ish.

Nice rise well done all. I Think EVG will do the same next week so sticking with them

19 ask now. come on 20p ;-)

It tells me there is limited stock. Every buy ticks this up. So should build in anticipation of news next week

Well I can’t buy any volume at 18.5p and I can sell at over 18p
So what does that tell you son?

Moving. Think this will be over 20p today

Seemingly just over 6 million shares to flog. It’s going to be volatile

http://evgen.com/wp-content/uploads/2019/02/EVG-Company-Presentation-Feb19-FINAL.pdf

the first 20 patients, 4 patients had their progressive disease stabilised for at least 24 weeks and a further 2 for 18 weeks
- Two patients that, at one scan, showed a partial response (i.e. tumour shrinkage over 30%) ? Principal Investigator, Dr Sacha Howell of the Christie Hospital, UK, said:
“The design of the STEM study, adding the drug to endocrine therapy on which a patient’s cancer was progressing, sets a high bar for SFX-01. In light of this, these interim results are highly encouraging. Objective responses indicate activity in this setting, and disease stabilisation for 6-12+ months represents clinically meaningful prolongation of response.

Looking good guys. Float is fiddly and small buys tick this up.
Game changing news due next week

Opening should be strong. Free float I make at 36% and someone had paid 20 grand over ask.
I think we should be at 20p tomorrow

See post below. Royalties double digit. Initial payment between 50 and 250 million dollars.
This is going to be a good week I reckon